Skip to main content
Premium Trial:

Request an Annual Quote

Q4 Revenues up, but Losses Widen for Exelixis

NEW YORK, Feb. 17 (GenomeWeb News) - Exelixis today reported an increase in revenues for the quarter ended Dec. 31, 2003, along with higher net losses and rising R&D expenses.

Exelixis posted total revenues of $13.8 million for the fourth quarter, up from $12.5 million in the same period of 2002.

The company's net loss widened to $23.3 million from $20.9 million in the fourth quarter of 2002.

R&D expenses for the quarter were $32.6 million, compared to $27.7 million for the equivalent period of 2002. Exelixis said the increase in R&D spending was due to its expanded drug discovery and development operations and clinical and preclinical development programs.

As of Dec. 31, 2003, the company's cash, cash equivalents, short-term investments, and restricted cash totaled $241.9 million, compared to $222.0 million at the end of 2002.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.